泰索帝联合顺铂与吉西他滨联合顺铂治疗非小细胞肺癌的临床观察

目的 探讨泰索帝联合顺铂与吉西他滨联合顺铂治疗非小细胞肺癌（NSCLC）的疗效、生存期及毒副作用。方法 28例经组织学或细胞学确诊的未曾治疗的晚期非小细胞肺癌（NSCLC），随机分为泰索帝联合顺铂（DC）治疗组（14例）、吉西他滨联合顺铂治疗组（GC）（14例）。结果 DC组有效率为42．85％（CR2例，PR4例），一生存率57．1％，中位生存期（MST）8．5个月，TTP 5．05个月，中位缓解期（MRT）9．5个月。GC组有效率为38．46％（CRI例，PR4例），一生存率38．5％，中位生存期（MST）8个月，TTP 3．89个月，中位缓解期（MRT）8．26个月。WHO血液学毒性评价，Ⅲ／Ⅳ度中性粒细胞下降，DC组：21．4％，GC组：为15．4％；Ⅲ／Ⅳ度血小板减少，DC组：7．1％，GC组：15．4％；Ⅲ／Ⅳ度血红蛋白下降，DC组：7．1％，GC组：7．7％；Ⅱ-Ⅳ度感觉神经病变发生率：DC组：14．3％；GC组：7．7％，；胃肠道反映，Ⅱ／Ⅲ呕吐发生率DC组：（14．3％）明显优于GC组：（53．8％）（P〈0．05）。结论 DC、GC方案对非小细胞肺癌，显示了相似的有效率，中位生存期及1年生存率。DC组胃肠道反应，Ⅱ／Ⅲ呕吐发生率明显低于GC组，为耐受性较好的治疗晚期NSCLC化疗方案。

The Clinical Observation of Combination of docetaxel and cisplatin or gemcitabine and cisplatin for the treatment of advanced non-small cell lung cancer

Objective To evaluate and compare effects the combination of docetaxel and cisplatin or gemcitabine and cisplatin for the treatment of advanced non-small cell lung cancer(NSCLC) Methods:The 28 cases with non-treatment advanced NSCLC diagnosed by pathologic or cytologic examination were automaticly divided into docetaxel and cisplatin group (DC)(14), gemcitabine and cisplatin groups(GC)(13), Results:The overall response rate of DC group was 42.85% (CR2, PR4) , one year survival rate was 57.1% , MST was 8 .5months , MTTP was 5.05 months, MRT was 9.5 months. For GC group, the overall response rate of this group was 38.46% (CR1, PR4) , one year survival rate was 38.5% , MST was 8 .0months , MTTP was3.89 months, MRT was 8.26 months.There were no significant difference in response rate, l- ySR,MTTP,MRT and MST for these two groups ( P > 0.05) . WHO grades 3/4 neutropenia 21.4%in DC groups; 15.4%in GC groups. there were similar in two goups ( P > 0.05) . Grade 3/4 anemia occurred 7.1% in DC groups;7.7%in GC groups,The grade 3/4 thrombocyto-penia occured in 7.1% in DC groups;7.7% in GC groups, Nausea/vomiting 14.3% in DC groups; 7.7% in GC groups . Conclusion: There were no significant differen in the response of rate,1-Ysr,MST for two groups .GC might be better chemotherapeutic regi- ment for advanced NSCLC .